Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pazopanib hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 43 for your search:
Start Over
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer Who Have No Evidence of Disease after Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: E2810, NCI-2012-00723, CDR0000730383, ECOG-E2810, NCT01575548
Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 11I03, NCI-2011-02939, NCT01465659
Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105SAR101, NCI-2014-00305, NCT01975519
Pazopanib Hydrochloride and Paclitaxel as First-Line Therapy in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI 09-53, NCI-2010-00748, 2010-7443, PZP113567, NCT01107665
Pazopanib Hydrochloride and Paclitaxel in Treating Patients with Refractory Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BLDR0010, NCI-2011-00416, SU-04152010-5683, NCT01108055
Pazopanib Hydrochloride before Surgery in Treating Patients with Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE 4809, NCI-2010-01392, NCI-2010-01538, NCT01158521
Intensity-Modulated Radiation Therapy and Paclitaxel with or without Pazopanib Hydrochloride in Treating Patients with Anaplastic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0912, NCI-2011-02614, CDR0000688092, NCT01236547
Pazopanib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Previously Treated With First-Line Therapy Containing Bevacizumab
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 0921, NCI-2013-00950, NCT01107652, NCT01262820
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AAPSMCS1002, NCI-2012-00932, ACORN AAPSMCS1002, NCT01330966
Pazopanib Hydrochloride or Temsirolimus in Treating Patients With Metastatic or Locally Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0358, NCI-2011-01277, NCT01392183
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OER-SAR-043, NCI-2011-01314, IRB#11-042, NCT01462630
Pazopanib Hydrochloride and Anastrozole or Letrozole in Treating Patients With Advanced Hormone-Resistant Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117513, NCI-2012-00494, NCT01466972
Gemcitabine Hydrochloride with or without Pazopanib Hydrochloride in Treating Patients with Refractory Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: 7943, NCI-2012-00052, NCT01532687
Pazopanib Hydrochloride before Surgery in Treating Patients with Locally Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1028, NCI-2013-00943, 11-0457, NCT01361113
Gemcitabine Hydrochloride and Docetaxel or Pazopanib Hydrochloride in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: 101644, NCI-2012-00675, MUSC 101644, MUSC CTO 101644, PAZ115785, PZP115785, NCT01593748
Trebananib with or without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-122, NCI-2012-01289, CDR0000738785, P9048_A12PAMDREVW01, 9048, NCT01664182
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: AWACMOS1102, NCI-2013-01371, ACORN AWACMOS1102, NCT01759303
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1152, NCI-2012-02027, Mod11-003340-15, Mod11-003340-20, NCT01767636
Pazopanib Hydrochloride Followed by Surgery in Treating Patients with High-Risk Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IRB# 63129, NCI-2014-00453, 63129, HCI63129, PZP116921, NCT01832259
Pazopanib Hydrochloride in Treating Patients with Progressive Carcinoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A021202, NCI-2013-00831, ALLIANCE A021202, CALGB-A021202, NCT01841736
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Recurrent Glioblastoma Multiforme
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BTTC12-01, NCI-2015-00601, NCI-2014-00490, NCT01931098
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
Start Over